NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,265.37 mln
Float128 mln
Earnings Date11/11/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
28.18
Transformational upside
Relative Strength
13
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-23.99
Deeply negative
ROA
-23.00
Deeply negative
Business Description
Trevi Therapeutics is a clinical-stage drug development company focused on treating persistent coughing in patients with serious lung conditions, including idiopathic pulmonary fibrosis and other related diseases. Its lead drug candidate, Haduvio, is a slow-release oral pill currently being tested in multiple clinical trials. The company holds a licensing agreement with Keenova Therapeutics to develop and sell medicines based on the active ingredient nalbuphine hydrochloride. Founded in 2011, Trevi Therapeutics operates out of New Haven, Connecticut.
